Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Rasburicase.

J Easton1, S Noble, B Jarvis

  • 1Adis International Limited, Auckland, New Zealand. demail@adis.co.nz

Paediatric Drugs
|July 5, 2001
PubMed
Summary
This summary is machine-generated.

Rasburicase effectively reduces uric acid in patients with cancer, outperforming allopurinol. This uricolytic agent was well-tolerated, showing no renal insufficiency during clinical trials.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Methods for think-aloud interviews in health-related resource-use research: the PECUNIA RUM instrument.

Expert review of pharmacoeconomics & outcomes research·2023
Same author

The Rise of Supportive Oncology: A Revolution in Cancer Care.

Clinical oncology (Royal College of Radiologists (Great Britain))·2023
Same author

Proper understanding of recurrent stress urinary incontinence treatment in women (PURSUIT): a randomised controlled trial of endoscopic and surgical treatment.

Trials·2022
Same author

COVID-19 confessions: a qualitative exploration of healthcare workers experiences of working with COVID-19.

BMJ open·2020
Same author

Modelling the lifetime cost-effectiveness of radical prostatectomy, radiotherapy and active monitoring for men with clinically localised prostate cancer from median 10-year outcomes in the ProtecT randomised trial.

BMC cancer·2020
Same author

Measuring functional limitations after venous thromboembolism: Optimization of the Post-VTE Functional Status (PVFS) Scale.

Thrombosis research·2020
Same journal

Molluscum Contagiosum Treatments in Children: A Systematic Review with Network Meta-Analysis.

Paediatric drugs·2026
Same journal

Real-World Systemic Treatment Patterns and Outcomes of Children With Severe Alopecia Areata: A French Nationwide Study (ESTAPED ohort).

Paediatric drugs·2026
Same journal

Epinephrine Underuse for Anaphylaxis in Infants and Toddlers: A Practical Review for Pediatricians.

Paediatric drugs·2026
Same journal

Risks of Undertreatment and Overtreatment in Pediatric Inflammatory Bowel Disease: Navigating the Balance.

Paediatric drugs·2026
Same journal

Discontinuing Colchicine in Pediatric Familial Mediterranean Fever: Real-Life Experience from a Long-Term Follow-Up Cohort.

Paediatric drugs·2026
Same journal

Sirolimus Therapy and Dyslipidemia in Neonates and Infants: A Retrospective Cohort and Pharmacovigilance Analysis.

Paediatric drugs·2026
See all related articles

Area of Science:

  • Oncology
  • Pharmacology
  • Nephrology

Background:

  • Chemotherapy can induce hyperuricaemia in patients with haematological malignancies.
  • Elevated uric acid levels pose risks, including renal complications.
  • Rasburicase is a recombinant urate oxidase designed to treat hyperuricaemia.

Purpose of the Study:

  • To evaluate the efficacy and safety of rasburicase for preventing and treating chemotherapy-induced hyperuricaemia.
  • To compare rasburicase with allopurinol in managing elevated uric acid levels.
  • To assess the impact of rasburicase on renal function.

Main Methods:

  • Conducted 3 noncomparative and 1 randomized comparative trial.
  • Administered rasburicase intravenously at 0.15 or 0.2 mg/kg/day.

Related Experiment Videos

  • Monitored plasma uric acid levels and serum creatinine.

    • Main Results:

    • Significant reductions in plasma uric acid levels were observed.
    • Rasburicase demonstrated a 2.6-fold greater reduction in uric acid exposure compared to oral allopurinol.
    • No evidence of renal insufficiency was found; creatinine levels remained stable.
    • Adverse events like skin rashes (approx. 2%), bronchospasm, nausea, vomiting, and haemolysis were infrequent and often associated with prior chemotherapy.

    Conclusions:

    • Rasburicase is an effective uricolytic agent for managing hyperuricaemia in cancer patients.
    • It offers a superior reduction in uric acid levels compared to allopurinol.
    • Rasburicase is generally well-tolerated with a favorable safety profile regarding renal function.